Abstract
Abstract
Rationale
Alcohol use disorder is a common and devastating mental illness for which satisfactory treatments are still lacking. Nalmefene, as an opioid receptor modulator, could pharmacologically support the reduction of drinking by reducing the (anticipated) rewarding effects of alcohol and expanding the range of treatment options. It has been hypothesized that nalmefene acts via an indirect modulation of the mesolimbic reward system. So far, only a few imaging findings on the neuronal response to nalmefene are available.
Objectives
We tested the effect of a single dose of 18 mg nalmefene on neuronal cue-reactivity in the ventral and dorsal striatum and subjective craving.
Methods
Eighteen non-treatment-seeking participants with alcohol use disorder (67% male, M = 50.3 ± 13.9 years) with a current high-risk drinking level (M = 76.9 ± 52 g of pure alcohol per day) were investigated using a cue-reactivity task during functional magnetic resonance imaging (fMRI) in a double-blind, placebo-controlled, cross-over study/design. In addition, self-reported craving was assessed before and after exposure to alcohol cues.
Results
An a priori defined region of interest (ROI) analysis of fMRI data from 15 participants revealed that nalmefene reduced alcohol cue-reactivity in the ventral, but not the dorsal striatum. Additionally, the subjective craving was significantly reduced after the cue-reactivity task under nalmefene compared to placebo.
Conclusion
In the present study, reduced craving and cue-reactivity to alcohol stimuli in the ventral striatum by nalmefene indicates a potential anti-craving effect of this drug via attenuation of neural alcohol cue-reactivity.
Funder
Deutsche Forschungsgemeinschaft
Publisher
Springer Science and Business Media LLC
Reference66 articles.
1. Ambrogne JA (2002) Reduced-risk drinking as a treatment goal: what clinicians need to know. J Subst Abus Treat 22:45–53. https://doi.org/10.1016/s0740-5472(01)00210-0
2. Annis H, Graham JM, Davis CS (1987) Inventory of drinking situations (IDS): user's guide. Addiction Research Foundation, Toronto
3. Anton RF (2008) Naltrexone for the management of alcohol dependence. N Engl J Med 359:715–721. https://doi.org/10.1056/NEJMct0801733
4. Babor TF, Higgins-Biddle JC, Saunders JB, Monteiro MG (2001) AUDIT. The alcohol use disorders identification test. Guidelines for Use in Primary Care, 2 edn. World Health Organization, Geneva, Switzerland
5. Bach P, Weil G, Pompili E, Hoffmann S, Hermann D, Vollstädt-Klein S, Mann K, Perez-Ramirez U, Moratal D, Canals S, Dursun SM, Greenshaw AJ, Kirsch P, Kiefer F, Sommer WH (2020) Incubation of neural alcohol cue reactivity after withdrawal and its blockade by naltrexone. Addict Biol 25:e12717. https://doi.org/10.1111/adb.12717
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献